Clearance of Nasal Staphylococcus Aureus With Triple Antibiotic Ointment
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00997139|
Recruitment Status : Completed
First Posted : October 19, 2009
Results First Posted : May 8, 2012
Last Update Posted : January 5, 2015
|Condition or disease||Intervention/treatment||Phase|
|Nasal Carriers of Staphylococcus Aureus||Drug: Neosporin (polymyxin B 5,000units, bacitracin 400 units, neomycin 3.5mg)||Not Applicable|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||216 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||Clearance of Nasal Staphylococcus Aureus Colonization With Triple Antibiotic Ointment|
|Study Start Date :||September 2009|
|Actual Primary Completion Date :||November 2010|
|Actual Study Completion Date :||November 2010|
- Drug: Neosporin (polymyxin B 5,000units, bacitracin 400 units, neomycin 3.5mg)
2 1/32oz packages will be dispensed. If positive nasal swab for S. aureus, subjects will apply a small amount to anterior nares twice daily for 5 days.
- Carrier Rate for Staphylococcus Aureus [ Time Frame: Baseline ]Percentage of subjects with baseline culture positive for Staphylococcus aureus (via nasal swab)
- MSSA Clearance Rate [ Time Frame: 14 days ]Percentage of subjects with methicillin-sensitive S. aureus on Baseline culture who achieved clearance with treatment.
- MRSA Clearance Rate [ Time Frame: 14 days ]Percentage of subjects with methicillin-resistant S. aureus on Baseline culture who achieved clearance with treatment.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00997139
|United States, Illinois|
|Chicago, Illinois, United States, 60611|
|Principal Investigator:||Peter Lio, MD||Northwestern Unviersity|